Rogaratinib
- Generic Name
- Rogaratinib
- Drug Type
- Small Molecule
- Chemical Formula
- C23H26N6O3S
- CAS Number
- 1443530-05-9
- Unique Ingredient Identifier
- 98BSN6N516
- Background
Rogaratinib is under investigation in clinical trial NCT03762122 (Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)).
Dana-Farber Researchers Present Breakthrough Cancer Studies at AACR 2025 Annual Meeting
• Dana-Farber Cancer Institute researchers are presenting multiple groundbreaking studies on head and neck, breast, and lung cancers at the 2025 AACR Annual Meeting in Chicago from April 25-30.
• Key presentations include Phase 3 results of pembrolizumab in head and neck cancer, promising combination therapies for metastatic breast cancer, and novel RAS inhibitors showing efficacy in lung cancer patients.
• The research spans innovative approaches including personalized cancer vaccines, targeted therapies for rare tumors, and digital health coaching interventions that demonstrate improved physical function in cancer survivors.
DelveInsight Report: Over 50 Pipeline Drugs in Development for Urothelial Carcinoma Treatment
• DelveInsight's latest pipeline analysis reveals 40+ pharmaceutical companies actively developing 50+ therapeutic candidates for urothelial carcinoma treatment, indicating robust research activity in this space.
• Major pharmaceutical companies including AstraZeneca, Seagen, and Janssen are advancing promising therapies, with notable candidates like disitamab vedotin and cetrelimab in late-stage development.
• Recent clinical trials include Seagen's Phase 2 study of disitamab vedotin with pembrolizumab, and Roche's Phase 1b/II umbrella study investigating multiple combination therapies for advanced urothelial carcinoma.
Rogaratinib Plus Atezolizumab Shows Promise in FGFR mRNA-Overexpressing Urothelial Cancer
• Rogaratinib combined with atezolizumab demonstrates activity in cisplatin-ineligible patients with advanced urothelial cancer overexpressing FGFR mRNA.
• In the FORT-2 trial, an objective response rate of 43% was observed across all patients, with a disease control rate of 65%.
• The recommended phase II dose of rogaratinib (600 mg) plus atezolizumab showed a 53.8% objective response rate and a 76.9% disease control rate.
• The combination therapy exhibited a manageable safety profile, suggesting broad potential benefit for patients with urothelial cancer.
Rogaratinib Plus Atezolizumab Shows Promise in Cisplatin-Ineligible Urothelial Cancer
• A phase 1b trial evaluated rogaratinib combined with atezolizumab in cisplatin-ineligible patients with advanced/metastatic urothelial carcinoma (UC) overexpressing FGFR mRNA.
• The recommended dose of rogaratinib 600 mg plus atezolizumab 1200 mg demonstrated a manageable safety profile and a high objective response rate of 53.8%.
• Efficacy was observed in tumors with low PD-L1 expression and was not dependent on FGFR3 gene alterations, suggesting broad potential benefit.
• The combination therapy provides a potential treatment option for patients with locally advanced/metastatic UC who are not eligible for cisplatin-based chemotherapy.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath